litlas
ログインアカウント作成

Daniil Stroyakovskiy

2010–2025 年に発表

69
論文数
22,615
被引用数
45
h 指数
64
i10 指数

被引用数

Daniil Stroyakovskiy の年別被引用数1999 年: 被引用 1 件2001 年: 被引用 1 件2003 年: 被引用 1 件2004 年: 被引用 1 件2011 年: 被引用 3 件2012 年: 被引用 1 件2013 年: 被引用 1 件2014 年: 被引用 17 件2015 年: 被引用 137 件2016 年: 被引用 145 件2017 年: 被引用 232 件2018 年: 被引用 228 件2019 年: 被引用 1,000 件2020 年: 被引用 1,167 件2021 年: 被引用 1,194 件2022 年: 被引用 1,083 件2023 年: 被引用 846 件2024 年: 被引用 1,640 件2025 年: 被引用 941 件2026 年: 被引用 19 件2000 年は被引用が無いため表示していません2002 年は被引用が無いため表示していません2005〜2010 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,424 件、この内訳の 20.4%中国: 引用元論文 1,512 件、この内訳の 12.7%イタリア: 引用元論文 863 件、この内訳の 7.3%ドイツ: 引用元論文 643 件、この内訳の 5.4%フランス: 引用元論文 632 件、この内訳の 5.3%イギリス: 引用元論文 606 件、この内訳の 5.1%スペイン: 引用元論文 486 件、この内訳の 4.1%日本: 引用元論文 469 件、この内訳の 4%オーストラリア: 引用元論文 417 件、この内訳の 3.5%スイス: 引用元論文 363 件、この内訳の 3.1%カナダ: 引用元論文 316 件、この内訳の 2.7%オランダ: 引用元論文 308 件、この内訳の 2.6%
0%20.4%その他 23.8%

機関

分野

  • Medicine69.6%
  • Biochemistry, Genetics and Molecular Biology24.9%
  • Immunology and Microbiology2.7%
  • Engineering0.6%
  • Computer Science0.6%
  • Materials Science0.3%
  • その他1.3%

トピック

  • Cancer Immunotherapy and Biomarkers13.8%
  • Melanoma and MAPK Pathways7%
  • Lung Cancer Treatments and Mutations6.9%
  • Lung Cancer Research Studies3.9%
  • Cutaneous Melanoma Detection and Management3.6%
  • Immunotherapy and Immune Responses3.5%
  • その他61.3%

共著者

全論文

検索で開く
  1. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    著者: Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck - New England Journal of Medicine 2018 被引用: 3,753

  2. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

    著者: Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin, Do‐Youn Oh, Susana Banerjee, Antonio González-Martı́n, Kyung Hae Jung, Iwona Ługowska, Luís Manso, Aránzazu Manzano, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Anitra Fielding, Yan Ma, Soham D. Puvvada, Norah J. Shire, Jung‐Yun Lee - Journal of Clinical Oncology 2023 被引用: 931

  3. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

    著者: Shukui Qin, Stephen L. Chan, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, А. В. Султанбаев, Monika Pazgan−Simon, Margaryta Pisetska, Davide Melisi, Davide Melisi, Yurii Osypchuk, Ivan Sinielnikov, Tsai‐Sheng Yang, Liang Xiao, Chunxia Chen, Linna Wang, Linna Wang, Ahmed O. Kaseb, Arndt Vogel, Shukui Qin, Shukui Qin, Shukui Qin, Ahmed O. Kaseb, Arndt Vogel, Shanzhi Gu, Arndt Vogel, Zhenggang Ren, Xiaoyan Lin, Zhenggang Ren, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Jianping Xiong, Wei Li, Yajin Chen, Yong Zeng, А. В. Султанбаев, Monika Pazgan−Simon, Margaryta Pisetska, Davide Melisi, Margaryta Pisetska, Yurii Osypchuk, Ivan Sinielnikov, Tsai‐Sheng Yang, Liang Xiao, Chunxia Chen, Linna Wang, Mingxiang Zhang, Li Xu, Xianglin Yuan, Da Li, Jierer Ying, Jingdong Zhang, Tao Zhang, Kangsheng Gu, Yifu He, Kangsheng Gu, Da Jiang, Shu Zhang, Baocai Xing, Baihong Zhang, Dong Wang, Xiaofeng Zhai, Houjie Liang, Bożena Cybulska-Stopa, Mikhail Dvorkin, Daniil Stroyakovskiy, M. Nechaeva, Chia‐Jui Yen, Wei‐Wen Su, Yen‐Hao Chen, Igor Bondarenko, Lin Yang, Weijia Fang, Carlos Gómez-Martín, Min‐Hee Ryu, Hansang Kim, Jeehyun Kim, Oleg Zarubenkov ほか 38 名 - The Lancet 2023 被引用: 679

  4. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

    著者: Caroline Robert, Jean‐Jacques Grob, Daniil Stroyakovskiy, Bogusława Karaszewska, Axel Hauschild, E. Levchenko, Vanna Chiarion‐Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko, Helen Gogas, Mario Mandalà, John B.A.G. Haanen, Célèste Lebbé, Andrzej Maćkiewicz, Piotr Rutkowski, Paul Nathan, Antoni Ribas, Michael A. Davies, Keith T. Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, Maurizio Voi, Dirk Schadendorf, Georgina V. Long - New England Journal of Medicine 2019 被引用: 1,376

  5. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

    著者: Mark A. Socinski, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Shengchun Kong, Anthony Lee, Shelley Coleman, Wei Zou, Mark L. McCleland, Geetha Shankar, Martin Reck - Journal of Thoracic Oncology 2021 被引用: 523

  6. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

    著者: Gerald W. Prager, Julien Taı̈eb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Élez, Felipe Melo Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Pápai, Pierre-Guillaume Poureau, Gábor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik Paul Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loïck Vidot, Josep Tabernero - New England Journal of Medicine 2023 被引用: 428

  7. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

    著者: Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski, Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski - The Lancet Respiratory Medicine 2019 被引用: 939

  8. Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

    著者: Byoung Chul Cho, Shun Lu, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Jong-Seok Lee, Se-Hoon Lee, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Benjamin Besse, Ki-Hyeong Lee, Hailin Xiong, Soon-Hin How, Ying Cheng, Gee‐Chen Chang, Hiroshige Yoshioka, James Chih‐Hsin Yang, Michael J. Thomas, Danny Nguyen, Sai‐Hong Ignatius Ou, Sanjay Mukhedkar, Kumar Prabhash, M. D’Arcangelo, Jorge Alatorre-Alexander, Juan Carlos Vázquez Limón, Sara Alves, Daniil Stroyakovskiy, Marina Peregudova, Mehmet Alı Nahıt Şendur, Ozan Yazıcı, Raffaele Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, Antonio Passaro, Sang‐We Kim, Shirish M. Gadgeel, John Xie, Tao Sun, Melissa Martínez, Mariah Ennis, E. Fennema, Mahesh Daksh, Dawn Millington, Isabelle Leconte, Ryota Iwasawa, Patricia Lorenzini, Mahadi Baig, Sujay Shah, Joshua Bauml, S. Martin Shreeve, Seema Sethi, R.E. Knoblauch, Hidetoshi Hayashi - New England Journal of Medicine 2024 被引用: 375

  9. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

    著者: Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl D. Lewis, Светлана Проценко, Rodrigo Perez Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Georgy M. Manikhas, Yibing Yan, Kuan-Chieh Huang, Anne Uyei, Virginia McNally, Grant A. McArthur, Paolo A. Ascierto - The Lancet 2020 被引用: 650

  10. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    著者: Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Célèste Lebbé, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John B.A.G. Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Н. В. Коваленко, Peter Mohr, Volodymyr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J. DeMarini, Jhangir G Irani, Michelle Casey, Danièle Ouellet, Anne‐Marie Martin, Ngocdiep T. Le, Kiran Patel, Keith T. Flaherty - New England Journal of Medicine 2014 被引用: 1,871

  11. Ribociclib plus Endocrine Therapy in Early Breast Cancer

    著者: Dennis J. Slamon, Oleg Lipatov, Zbigniew Nowecki, Nicholas P. McAndrew, Bożena Kukiełka-Budny, Daniil Stroyakovskiy, Denise A. Yardley, Chiun‐Sheng Huang, Peter A. Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock‐Ah Im, Manuel Ruíz-Borrego, Sherene Loi, Binghe Xu, Sara A. Hurvitz, Carlos H. Barrios, Michael Untch, Rebecca Moroose, F. Visco, Karen Afenjar, Rodrigo Fresco, Irene Severin, Yan Ji, Farhat Ghaznawi, Zheng Li, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Gabriel N. Hortobágyi - New England Journal of Medicine 2024 被引用: 357

  12. Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

    著者: James Larkin, Paolo A. Ascierto, Brigitte Dréno, Victoria Atkinson, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, L. Thomas, Luis de la Cruz‐Merino, Caroline Dutriaux, Claus Garbe, Mika A. Sovak, Ilsung Chang, Nicholas W. Choong, Stephen P. Hack, Grant A. McArthur, Antoni Ribas - New England Journal of Medicine 2014 被引用: 2,032

  13. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

    著者: Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, B. Yа. Alekseev, Francis Parnis, Vagif Atduev, Gary L. Buchschacher, Rustem Gafanov, Luis Corrales, Michael Borre, Daniil Stroyakovskiy, Gustavo Vasconcelos Alves, Evangelos Bournakis, Javier Puente, Marie-Laurence Harle-Yge, Jorge D. Gallo, Geng Chen, Justin Hanover, Matthew Wongchenko, Josep Garcia, Johann S. de Bono - The Lancet 2021 被引用: 329

  14. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

    著者: Naoyuki Nogami, Fabrice Barlési, Mark A. Socinski, Martin Reck, Christian A. Thomas, Federico Cappuzzo, Tony Mok, Gene Grant Finley, Joachim G.J.V. Aerts, Francesco Orlandi, Denis Moro‐Sibilot, Robert M. Jotte, Daniil Stroyakovskiy, Liza C. Villaruz, Delvys Rodríguez‐Abreu, Wan‐Teck Lim, David M. Merritt, Shelley Coleman, Anthony Lee, Geetha Shankar, Wei Yu, Ilze Bāra, Makoto Nishio - Journal of Thoracic Oncology 2021 被引用: 303

  15. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

    著者: Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Maen Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, Kuan-Chieh Huang, Vilma Graupner, Shawn W. Sun, Tien Hoang, Helen Jessop, Mark L. McCleland, Marcus Ballinger, Alan Sandler, Mark A. Socinski - Journal of Thoracic Oncology 2020 被引用: 607

  16. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    著者: Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Célèste Lebbé, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John B.A.G. Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Н. В. Коваленко, Peter Mohr, Volodymr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J. DeMarini, Jhangir G Irani, S. Swann, Jeffrey J. Legos, Fan Jin, Bijoyesh Mookerjee, Keith T. Flaherty - The Lancet 2015 被引用: 1,386

  17. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

    著者: Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno, Victoria Atkinson, Gabrielle Liszkay, Anna Maria Di Giacomo, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, L. Thomas, Luis de la Cruz‐Merino, Caroline Dutriaux, Claus Garbe, Yibing Yan, Matthew Wongchenko, Ilsung Chang, Jessie J. Hsu, Daniel O. Koralek, Isabelle Rooney, Antoni Ribas, James Larkin - The Lancet Oncology 2016 被引用: 1,005

  18. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

    著者: Sara A. Hurvitz, Miguel Martín, W. Fraser Symmans, Kyung Hae Jung, Chiun‐Sheng Huang, Alastair M. Thompson, Nadia Harbeck, Vicente Valero, Daniil Stroyakovskiy, Hans Wildiers, Mario Campone, Jean-François Boileau, Matthias W. Beckmann, Karen Afenjar, Rodrigo Fresco, Hans‐Joachim Helms, Jin Xu, Yvonne G. Lin, Joseph A. Sparano, Dennis J. Slamon - The Lancet Oncology 2017 被引用: 529

  19. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    著者: Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci ほか 32 名 - The Lancet Oncology 2021 被引用: 389

  20. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib forBRAFV600–Mutant Unresectable or Metastatic Melanoma

    著者: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean Jacques Grob, Nicolas Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf - Journal of Clinical Oncology 2022 被引用: 163

  21. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

    著者: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul Nathan, Piotr Rutkowski, О. В. Леонов, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean‐Jacques Grob, Nicolás Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steve Green, T Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf - 2022 被引用: 146

  22. 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

    著者: Paolo A. Ascierto, Brigitte Dréno, James Larkin, Antoni Ribas, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, L. Thomas, Luis de la Cruz‐Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Jessie J. Hsu, S.C. Bowen Jones, Haocheng Li, Edward McKenna, Athina Voulgari, Grant A. McArthur - Clinical Cancer Research 2021 被引用: 182

  23. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.

    著者: Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin, Do‐Youn Oh, Susana Banerjee, Antonio González-Martı́n, Kyung Hae Jung, Iwona Ługowska, Luís Manso, Aránzazu Manzano, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Chiedozie Anoka, Yan Ma, Soham D. Puvvada, Jung‐Yun Lee - Journal of Clinical Oncology 2023 被引用: 86

  24. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

    著者: G.V. Long, K.T. Flaherty, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, Vanna Chiarion‐Sileni, C. Lebbe, M. Mandalá, M. Millward, Ana Arance, Igor Bondarenko, J.B.A.G. Haanen, J. Hansson, Jochen Utikal, Virginia Ferraresi, P. Mohr, V. Probachai, Dirk Schadendorf, Paul Nathan, C. Robert, A. Ribas, M.A. Davies, S.R. Lane, J.J. Legos, B. Mookerjee, Jean‐Jacques Grob - Annals of Oncology 2017 被引用: 652